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The authors have noted an error in Figure 6A of the originally published version of this article. The image for pERK (top right panel) was
incorrectly duplicated from Figure 4E (top right panel). The corrected Figure 6 is shown here. This error does not alter the original
conclusions of the study, but the authors wish to apologize for this oversight and any confusion that may have resulted.A B C
Figure 6. CCT196969 and CCT241161 Inhibit Tumors with Acquired Resistance to Dabrafenib plus Trametinib466 Cancer Cell 31, 466, March 13, 2017 ª 2017 The Author(s). Published by Elsevier Inc.
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